Exabis Library
Welcome to the e-CCO Library!
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn’s Disease and ulcerative colitis from the NOR-SWITCH trial
2017
ECCO'17 Barcelona
1
DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s Disease: Endoscopic effects of induction therapy
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP063: Measurement of Endoscopic Severity in a Crohn's Disease Multi-Centre Pediatric Inception Cohort: Poor correlation of SES-CD with PCDAI
2016
ECCO'16 DOP
1
DOP063: Measurement of endoscopic severity in a Crohn’s disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohn’s Disease Activity Index (PCDAI)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in Inflammatory Bowel Disease patients
2017
ECCO'17 Barcelona
1
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
2016
ECCO'16 DOP
1
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP064: ECCO expert consensus and topical review on treatment exit strategies in Inflammatory Bowel Disease
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in Inflammatory Bowel Disease patients with primary sclerosing cholangitis
2017
ECCO'17 Barcelona
1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulators
2016
ECCO'16 DOP
1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn’s patients on concomitant immunomodulators
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP065: Long term cost effectiveness of tight control for Crohn’s Disease with adalimumab-based treatment: Economic evaluation beyond 48 weeks of CALM trial
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1